Welcome to The Body PRO Newsletter, a bi-weekly review of the latest breaking news and research in HIV medicine, aimed specifically at informing health care professionals.

February 23, 2011

In This Newsletter:

  HIV TREATMENT & COMPLICATIONS

Coming Next Week: Coverage of CROI 2011 in Boston, Mass.
The largest annual gathering of HIV researchers and clinicians begins this weekend, and TheBodyPRO.com will be on hand to bring you wide-ranging coverage. Visit our CROI 2010 home page frequently for key study summaries and a discussion of clinically relevant conference highlights!


Is the "Non-Suppressive HIV Drug" KP-1461 Worth Getting Excited About?
Our search is unceasing for innovative antiretrovirals and other pharmaceutical inhibitors of HIV replication. One particularly intriguing current candidate is KP-1461, which attempts to induce mutations in the HIV genome that drastically reduce the virus's ability to reproduce. Paul Sax, M.D., tells us a bit about this drug in development, and takes a moment to "keep it real" on the topic of pipeline antiretrovirals.


Atazanavir Drug Label Updated With Adjusted Dose for Pregnant Women
Bristol-Myers Squibb Company announced on Feb. 7 that the U.S. Food and Drug Administration has approved an update to the labeling for atazanavir (Reyataz) to include dose recommendations in HIV-infected pregnant women, Positively Aware reports.


Phase 3 Study Begins for New Fixed-Dose Combination, 572-Trii
Shionogi-ViiV Healthcare announced on Feb. 3 that it has begun a Phase 3 study to assess the efficacy and safety of a new fixed-dose combination antiretroviral. The investigational drug, known as 572-Trii, is a combination of abacavir/lamivudine (Epzicom, Telzir) and the experimental integrase inhibitor S/GSK1349572. The study will pit the drug against efavirenz/tenofovir/emtricitabine (Atripla) in antiretroviral-naive HIV-infected volunteers.


More Headlines on HIV Treatment & Complications:


  Back to Top



  HIV NEWS & VIEWS

Obama's Proposed Budget Calls for Increases to HIV/AIDS Programs; Republicans Call for Cuts
Last week, the White House unveiled its budget proposal for the remainder of 2011, and the U.S. Office of National HIV/AIDS Policy discussed how the budget would impact HIV prevention and care. "While we've heard in the press that the new budget includes cuts in most social spending domestically, there is actually increased funding in most HIV-related programs," reports HIV/AIDS advocate Kenyon Farrow. The Republican budget proposal, however, tells a very different story.


Idaho Becomes 11th State With ADAP Waiting List; 6,452 Now on Lists Nationwide
The number of HIV-infected people in the U.S. on a waiting list to receive medications through their state's AIDS Drug Assistance Program has skyrocketed in recent months, reaching ever-higher record highs with little relief in sight. Most of those on waiting lists live in the South: Florida's waiting list is above 3,200, while Georgia's is nearing 1,000.


New Report Deeply Criticizes HIV/AIDS Spending, Decries Rampant Stigma
"Despite a more than 53-fold increase in AIDS funding in barely over a decade, the epidemic continues to outpace the rate at which programs are delivering," according to a new UNAIDS-commissioned report. The report finds that scarce resources are being misspent, while laws making homosexual sex illegal and the harassment of intravenous drug users are preventing the most vulnerable from seeking help.


HIV Criminalization Case Offers a Shocking Reminder of Ignorance in the U.S., Journalist Says
"No one is saying that [HIV-infected people] don't have an ethical obligation to disclose," writes journalist Todd Heywood. "The real question here is ... why are Americans of any sexual orientation abdicating their personal health and safety to another person's willingness or ability to disclose?" In a blog for The Bilerico Project, Heywood discusses how the immense societal ignorance around HIV transmission is "literally killing" gay men.


More News Headlines:


  Back to Top



  THE PATIENT PERSPECTIVE: FEATURED ON THEBODY.COM

Nelson VergelNelson Vergel: The Long-Term $urvivor Dilemma
"As we speak more [at conferences] about the science related to aging with HIV ... the communal anxiety of surviving and aging with HIV is not addressed," HIV activist and fitness guru Nelson Vergel warns. In the first entry of his new blog on TheBody.com, Nelson talks about an aspect of aging and HIV that's often overlooked by researchers: the effect it has on a person's wallet and his or her emotional well-being.


Dee BorregoHelping People Understand the Needs of the Transgender HIV Community
For Dee Borrego, an HIV-infected transgender person herself, witnessing the persecution her communities face has often led to frustration and heartbreak. But Dee still strongly believes that, "by being open and honest with those who have questions, we can educate and enlighten more people about what it means to be living with HIV and/or to be transgender nowadays." In this op-ed, Dee lets off a little steam and talks about how the transgender community can help build bridges between "us" and "them."


tilePositive Love: A Valentine's Day Video Collection
Ah, love: It's exhilarating, it's challenging, it's terrifying -- and when you're living with HIV, it involves all sorts of additional issues to consider. In honor of Valentine's Day, we put together this collection of videos featuring a diverse array of people -- HIV-positive and HIV-negative, gay and heterosexual, single and partnered -- as they share stories and advice on finding love when one is living with HIV.


Maria T. MejiaMaria T. Mejia: Why I'm Here
"My partner's sister passed away from cancer," recalls blogger Maria T. Mejia. "[I] asked myself, WHY can't I say I have HIV? Why is it that anyone can say they have cancer or diabetes or any other health condition and I am so scared to disclose openly without having that fear?" In this entry, Maria explains why, after 20 years of living with HIV, she's chosen now to go public about her status.


  Back to Top



  HIV/STD TRANSMISSION

tileThe Rising HIV Rates Among Young Women and Girls of Color: What's Going On? Part Two
In part two of this exclusive, two-part roundtable discussion, we take a critical look into HIV risk among young women in the U.S. A panel of prominent advocates explores the harsh social, cultural and economic realities that lead women and girls of color to put themselves in situations where they may be especially likely to get HIV -- and what must happen to break this destructive cycle.


Transforming Our Approach to HIV Prevention and Treatment
While transgender men and women appear to be at a heightened risk for HIV, there is little reliable research available about this community. In this Achieve article, Raquel Sapién and Robert Valadéz highlight some key facts about transgender people and HIV/AIDS -- including what data are out there, what factors make transgender people more vulnerable to HIV infection and how antiretrovirals may interact with hormone therapy.


More Headlines on HIV/STD Transmission:


  Back to Top


Advertisement



Also Worth Noting

Top HIV/AIDS Clinical Developments of 2010

David Wohl, M.D.

Of the hundreds of published studies, presented research and other major developments in HIV this year, which are the most likely to change the way we approach HIV prevention or the care of our HIV-infected patients?

In one of our most popular annual updates (available this year on TheBody.com), David Wohl, M.D., takes an in-depth look at the highlights of 2010 and their clinical implications.

HIV Management Today

In HIV Management Today, an informative online series from TheBodyPRO.com, we consult with some of the top clinical minds in HIV on some of the most important issues in HIV/AIDS clinical management.

•  Assessing and Acting on Cardiovascular Disease Risk in HIV-Infected Patients, featuring Marshall Glesby, M.D., Ph.D., and Jens Lundgren, M.D.

•  A Closer Look at Tesamorelin (Egrifta), a Newly Approved Treatment for HIV-Associated Lipohypertrophy, featuring Daniel Berger, M.D.

•  New Paradigms of First-Line HIV Therapy: Determining When (and With What) to Start, featuring Eric Daar, M.D., and Trevor Hawkins, M.D.

•  Clinical Management of the HIV-Infected Woman, featuring Kimberly Smith, M.D., M.P.H., and Valerie Stone, M.D., M.P.H.